How do you select among systemic agents for moderate-to-severe AD, including systemic immunotherapy with dupilumab? Where does this IL-4/IL-13 inhibitor fit into sequencing of therapy in pediatric and adolescent patients?

How do you select among systemic agents for moderate-to-severe AD, including systemic immunotherapy with dupilumab? Where does this IL-4/IL-13 inhibitor fit into sequencing of therapy in pediatric and adolescent patients?

How do you select among systemic agents for moderate-to-severe AD, including systemic immunotherapy with dupilumab? Where does this IL-4/IL-13 inhibitor fit into sequencing of therapy in pediatric and adolescent patients? 


Created by

CMEducation Resources iQ&A Case-By-Case Atopic Dermatitis Medical Intelligence Zone

Presenter

Lawrence Eichenfield, MD

Lawrence Eichenfield, MD

Chief of Pediatric and Adolescent Dermatology
Rady Children's Hospital-San Diego
Vice Chair, Department of Dermatology
Professor of Dermatology and Pediatrics
UC San Diego School of Medicine